Alnylam Pharmaceuticals, Inc. ALNY
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.46B | 1.29B | 1.17B | 1.10B | 1.25B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.46B | 1.29B | 1.17B | 1.10B | 1.25B |
| Cost of Revenue | 361.75M | 298.45M | 211.12M | 267.72M | 200.15M |
| Gross Profit | 1.10B | 992.50M | 956.05M | 829.31M | 1.05B |
| SG&A Expenses | 342.00M | 347.92M | 322.55M | 325.37M | 322.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.11B | 1.06B | 898.54M | 965.32M | 881.04M |
| Operating Income | 345.80M | 231.44M | 268.64M | 131.72M | 367.98M |
| Income Before Tax | 295.81M | 177.81M | 221.65M | 161.14M | 280.57M |
| Income Tax Expenses | -1.87B | 13.31M | 15.66M | -25.28M | -12.12M |
| Earnings from Continuing Operations | 2.17B | 164.49M | 205.99M | 186.42M | 292.68M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.17B | 164.49M | 205.99M | 186.42M | 292.68M |
| EBIT | 345.80M | 231.44M | 268.64M | 131.72M | 367.98M |
| EBITDA | 360.27M | 245.34M | 282.19M | 145.22M | 381.79M |
| EPS Basic | 16.19 | 1.23 | 1.55 | 1.41 | 2.23 |
| Normalized Basic EPS | 1.38 | 0.83 | 1.04 | 0.58 | 1.52 |
| EPS Diluted | 15.72 | 1.21 | 1.51 | 1.37 | 2.14 |
| Normalized Diluted EPS | 1.34 | 0.80 | 1.00 | 0.56 | 1.45 |
| Average Basic Shares Outstanding | 133.83M | 133.61M | 132.89M | 132.23M | 131.45M |
| Average Diluted Shares Outstanding | 138.04M | 138.28M | 138.23M | 136.28M | 137.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |